SAMA Inhaler (Ipratropium Bromide) Use
Ipratropium bromide should NOT be used as first-line monotherapy but rather added to short-acting beta-agonists (SABAs) specifically for severe asthma exacerbations or as maintenance therapy in COPD. 1, 2
Dosing
For Asthma Exacerbations (Acute Use Only)
Nebulizer Solution (0.25 mg/mL):
- Adults: 0.5 mg every 20 minutes for 3 doses, then as needed 1, 2
- Children: 0.25-0.5 mg every 20 minutes for 3 doses, then as needed 1, 2
MDI (18 mcg/puff):
- Adults: 8 puffs every 20 minutes as needed up to 3 hours 1, 2
- Children: 4-8 puffs every 20 minutes as needed up to 3 hours 1, 2
- Must use with valved holding chamber (VHC) and face mask for children <4 years 1
Critical limitation: The addition of ipratropium has NOT been shown to provide further benefit once the patient is hospitalized—it is only beneficial in the emergency department setting during the first 3 hours 1, 2
For COPD (Maintenance Therapy)
Standard dosing: 500 mcg (one unit-dose vial) administered 3-4 times daily by nebulizer, with doses 6-8 hours apart 3
Alternative: 2 puffs (36-42 mcg) four times daily via MDI 4
Inhalation Technique
Nebulizer Administration 3:
- Twist open unit-dose vial and squeeze entire contents into nebulizer reservoir
- Connect reservoir to mouthpiece or face mask
- Connect nebulizer to compressor
- Sit upright, place mouthpiece in mouth (or apply face mask)
- Critical safety point: If using face mask, ensure tight seal to prevent solution contact with eyes—can cause pupil dilation, blurred vision, or precipitate narrow-angle glaucoma 3
- Breathe calmly and deeply until no mist forms (approximately 5-15 minutes)
MDI Technique 1:
- Requires slow inhalation (30 L/min or 3-5 seconds) during actuation
- Follow with 10-second breath-hold
- Coordination of actuation with inhalation is critical—many patients struggle with this, particularly elderly 1
- Use with spacer/VHC significantly improves delivery and reduces oropharyngeal deposition
Drug Mixing
Can be mixed with: Albuterol or metaproterenol in the same nebulizer if used within 1 hour 3
Cannot be mixed with: Any other drugs—stability and safety not established 3
Contraindications
Absolute contraindication: Known hypersensitivity to ipratropium bromide, atropine, or atropine derivatives 3
Relative contraindications/precautions:
- Narrow-angle glaucoma (risk of precipitation or worsening if solution contacts eyes) 3
- Bladder neck obstruction (though safer than atropine) 5
- Prostatic hyperplasia
Common Side Effects
The drug is remarkably well-tolerated with minimal systemic absorption when inhaled properly 4, 5:
Most common (generally mild):
Less common:
- Nausea
- Nervousness
- Gastrointestinal distress
- Dizziness 6
Does NOT cause:
- Tremor or tachycardia (unlike beta-agonists) 5
- Significant effects on mucus production, viscosity, or clearance 5
Key Clinical Pearls
Onset and duration:
- Onset: 15-30 minutes (slower than SABAs) 7, 6
- Peak effect: 30-90 minutes 7
- Duration: 4-6 hours for ipratropium 7
Why it's not first-line in asthma: The delayed onset makes it unsuitable as monotherapy for acute bronchospasm—SABAs remain the treatment of choice for immediate symptom relief 1, 6
When it adds value: In severe asthma exacerbations in the ED, combining ipratropium with albuterol provides additive bronchodilation superior to either agent alone 1, 2. However, this benefit disappears once patients are hospitalized 1, 2.
COPD vs Asthma: Ipratropium is more effective in COPD than in asthma and may be superior to beta-agonists in chronic bronchitis and emphysema 5, 8. For COPD, long-acting muscarinic antagonists (LAMAs like tiotropium) are preferred over ipratropium for maintenance therapy 9, 10.
Storage: Store between 15-30°C (59-86°F), protect from light, keep in pouch until use 3